[Weight loss in a patient with morbid obesity under treatment with oleoyl-estrone].
OBJECTIVE
Oleoyl-estrone administration in rats results in loss of body fat and sparing protein via decreasing food intake and maintaining energy expenditure. Oleoyl-estrone also decreases insulin resistance and hyperlipidemia and has no direct estrogenic effects. Our objective was to determine whether oral oleoyl-estrone was effective in the treatment of morbid obesity in a voluntary patient.


METHODS
Oleoyl-estrone (150-300 mol/d) was given to a morbid obese man (BMI: 51.9) over 10 consecutive 21-day trial periods of oral drug intake followed by at least two months of recovery. This treatment was given without additional dietary restrictions. Plasma metabolites, hormones and enzymes were measured before treatment, during active administration and at recovery periods.


RESULTS
Oleoyl-estrone decreased the body weight (38.5 kg in 27 months, final BMI: 40.5). No rebound trends were observed. No significant changes in blood parameters, plasma metabolites, hormones or enzymes were observed as a consequence of the treatment.


CONCLUSIONS
Oleoyl-estrone decreased body weight in this subject without affecting metabolites or hormones, similarly to its effects in animal models. This means that oleoyl-estrone could have a marked potential as an anti-obesity drug.
Alemany
Marià
M
Centre Especial de Recerca en Nutrició i Ciència dels Aliments. Facultat de Biologia. Universitat de Barcelona. Barcelona. Spain. malemany@ub.edu
Fernández-López
José Antonio
JA
Petrobelli
Angelo
A
Granada
Marisa
M
Foz
Màrius
M
Remesar
Xavier
X
D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D004970:Estrone / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009767:Obesity, Morbid / Q000188:drug therapy*; D009829:Oleic Acids / Q000627:therapeutic use*
D019440:Anti-Obesity Agents; D009829:Oleic Acids; D004970:Estrone; C108709:oleoyl-estrone